$54.30
Manufacturer: Ukraine
Preventive treatment of bronchial asthma Large Mild asthma: patients who require periodic symptomatic treatment with bronchodilators daily. Moderate asthma: patients with unstable asthma or with worsening of the condition against the background of existing preventive therapy or therapy with bronchodilators only. Severe asthma: patients with severe chronic asthma and patients dependent on systemic corticosteroids for adequate symptom control. After starting the use of inhaled fluticasone propionate, many such patients will be able to significantly reduce or completely abandon the oral use of corticosteroids. Symptomatic therapy of chronic obstructive pulmonary diseases (COPD).
Description
FLUTIXON 250 mcg COMPOSITION
active substance: fluticasonum
1 capsule contains fluticasone propionate 125 mcg or 250 mcg
Excipients: lactose, lactose.
FLUTIXON 250 mcg DOSAGE FORM
Inhalation powder, hard capsules.
FLUTIXON 250 mcg MAIN PHYSICAL AND CHEMICAL PROPERTIES:
PHARMACOLOGICAL GROUP
Other medicines for the treatment of obstructive airways disease. Inhaled glucocorticosteroids. ATX code R03B A05.
PHARMACOLOGICAL PROPERTIES
Pharmacological.
Fluticasone propionate, when administered by inhalation in recommended doses, has a pronounced glucorticoid anti-inflammatory effect in the lungs. This is manifested in a decrease in both symptoms and exacerbations of asthma with a decrease in the number and intensity of adverse reactions compared with systemic use of corticosteroids.
Pharmacokinetics.
The average systemic bioavailability of Fluticson according to studies in healthy volunteers was 28.6%. Systemic absorption is carried out mainly through the respiratory system, first quickly, then – for a long time. The remainder of the inhalation dose can be swallowed.
Product safety data
Toxicological studies have shown the presence of effects typical of strong GCS, but in doses many times higher than those indicated for therapeutic use. In studies on the effect of the drug on reproductive function and the presence of teratogenic properties of the drug, no new data were found. Fluticasone propionate has no mutagenic activity in vitro and in vivo. In experiments on animals, it was shown that there is no carcinogenic potential in the preparation, as well as irritating and sensitizing properties.
INDICATIONS
Preventive treatment of bronchial asthma
adults
Mild asthma: patients who need periodic symptomatic treatment with bronchodilators daily.
Moderate asthma: Patients with unstable asthma or worsening with existing prophylactic therapy or therapy with bronchodilators alone.
Severe asthma: Patients with severe chronic asthma and patients dependent on systemic corticosteroids for adequate symptom control. Once inhaled fluticasone propionate is started, many of these patients will be able to significantly reduce or completely eliminate oral corticosteroid use.
CHILDREN
Prophylactic anti-asthma treatment, including in the case when control of asthma symptoms has not been achieved against the background of treatment with other anti-asthma drugs.
CONTRAINDICATIONS
Hypersensitivity to the active substance or other components of the drug.
Recent Reviews